van Bezooijen R - Search Results

1

Sclerostin and the regulation of bone formation: Effects in hip osteoarthritis and femoral neck fracture.

Power J, Poole KE, van Bezooijen R, Doube M, Caballero-Alías AM, Lowik C, Papapoulos S, Reeve J, Loveridge N. Power J, et al. Among authors: van bezooijen r. J Bone Miner Res. 2010 Aug;25(8):1867-76. doi: 10.1002/jbmr.70. J Bone Miner Res. 2010. PMID: 20200987 Free article.

2

Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation.

Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Löwik CW, Reeve J. Poole KE, et al. FASEB J. 2005 Nov;19(13):1842-4. doi: 10.1096/fj.05-4221fje. Epub 2005 Aug 25. FASEB J. 2005. PMID: 16123173

3

Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover.

van Lierop AH, Hamdy NA, Hamersma H, van Bezooijen RL, Power J, Loveridge N, Papapoulos SE. van Lierop AH, et al. Among authors: van bezooijen rl. J Bone Miner Res. 2011 Dec;26(12):2804-11. doi: 10.1002/jbmr.474. J Bone Miner Res. 2011. PMID: 21786318 Free article.

4

Osteocyte recruitment declines as the osteon fills in: interacting effects of osteocytic sclerostin and previous hip fracture on the size of cortical canals in the femoral neck.

Power J, Doube M, van Bezooijen RL, Loveridge N, Reeve J. Power J, et al. Among authors: van bezooijen rl. Bone. 2012 May;50(5):1107-14. doi: 10.1016/j.bone.2012.01.016. Epub 2012 Jan 28. Bone. 2012. PMID: 22353552

5

SOST/sclerostin, an osteocyte-derived negative regulator of bone formation.

van Bezooijen RL, ten Dijke P, Papapoulos SE, Löwik CW. van Bezooijen RL, et al. Cytokine Growth Factor Rev. 2005 Jun;16(3):319-27. doi: 10.1016/j.cytogfr.2005.02.005. Cytokine Growth Factor Rev. 2005. PMID: 15869900 Review.

6

Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation.

van Bezooijen RL, Svensson JP, Eefting D, Visser A, van der Horst G, Karperien M, Quax PH, Vrieling H, Papapoulos SE, ten Dijke P, Löwik CW. van Bezooijen RL, et al. J Bone Miner Res. 2007 Jan;22(1):19-28. doi: 10.1359/jbmr.061002. J Bone Miner Res. 2007. PMID: 17032150 Free article.

7

Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling.

ten Dijke P, Krause C, de Gorter DJ, Löwik CW, van Bezooijen RL. ten Dijke P, et al. Among authors: van bezooijen rl. J Bone Joint Surg Am. 2008 Feb;90 Suppl 1:31-5. doi: 10.2106/JBJS.G.01183. J Bone Joint Surg Am. 2008. PMID: 18292354 Review.

8

Bone morphogenetic proteins and their antagonists: the sclerostin paradigm.

van Bezooijen RL, Papapoulos SE, Löwik CW. van Bezooijen RL, et al. J Endocrinol Invest. 2005;28(8 Suppl):15-7. J Endocrinol Invest. 2005. PMID: 16323824 Review.

9

Sclerostin: current knowledge and future perspectives.

Moester MJ, Papapoulos SE, Löwik CW, van Bezooijen RL. Moester MJ, et al. Among authors: van bezooijen rl. Calcif Tissue Int. 2010 Aug;87(2):99-107. doi: 10.1007/s00223-010-9372-1. Epub 2010 May 15. Calcif Tissue Int. 2010. PMID: 20473488 Free PMC article. Review.

10

Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist.

van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Löwik CW. van Bezooijen RL, et al. J Exp Med. 2004 Mar 15;199(6):805-14. doi: 10.1084/jem.20031454. J Exp Med. 2004. PMID: 15024046 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

39 results

Search Page

Filters